Phase II study of cediranib in patients with advanced gastrointestinal stromal tumours (GIST) or soft tissue sarcoma (STS).

CONCLUSIONS: In patients progressing on imatinib/sunitinib, cediranib 45 mg/day demonstrated evidence of activity by 18FDG-PET but did not reduce average SUVmax. Evidence of antitumor activity was seen in ASPS. PMID: 24714778 [PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24714778?dopt=Abstract

Source: Clinical Cancer Research - April 8, 2014 Category: Cancer & Oncology Authors: Judson IR, Scurr M, Gardner K, Barquin E, Marotti M, Collins B, Young H, Jurgensmeier J, Leahy M Tags: Clin Cancer Res Source Type: research